Q32 Bio Q3 2026 net loss widens 20% to $8.9 million year over year

PUBT · 1d ago
Q32 Bio Q3 2026 net loss widens 20% to $8.9 million year over year
  • Q32 Bio’s third-quarter 2026 net loss widened 20% year over year to $8.9 million.
  • Research and development expenses rose 42% to $5.1 million; general and administrative expenses climbed 38% to $5.5 million.
  • Cash and cash equivalents totaled $289.6 million at September 30, expected to fund operations through planned Phase 3 topline results.
  • A registration-directed bempikibart program for severe or very severe alopecia areata is expected to begin in first-half 2027, subject to regulatory discussions.
  • Bempikibart responses were maintained or deepened during SIGNAL-AA’s 16-week off-drug follow-up, supporting potential for less frequent maintenance dosing.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Q32 Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-446183), on November 04, 2026, and is solely responsible for the information contained therein.